The FDA has approved GlaxoSmithKline and Ligand Pharmaceuticals' Promacta (eltrombopag). The drug treats a rare immune condition called thrombocytopenia purpura, in which a patient's immune system attacks its own platelets. Promacta is the first oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic ITP. Release